Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 33
+1.10%-2.67%+62.79%+70.47% 67.53B
+1.28%+8.71%+13.96%+95.16% 60.74B
+0.36%-0.95%+20.09%+99.04% 55.66B
-0.96%+7.41%+10.20%+108.91% 47.97B
-1.25%+2.35%+22.74%+38.34% 45.24B
-2.41%-0.73%+167.89%+794.72% 39.08B
+1.21%-2.56%+20.27%+52.81% 35.34B
-0.87%-2.89%+79.60%+63.96% 33.45B
-2.22%+8.56%-39.26%+397.14% 26.49B
Average -0.38%+3.27%+39.81%+191.17% 46B
Weighted average by Cap. -0.17%+3.39%+40.40%+166.70%
Logo ARYx Therapeutics, Inc.
ARYx Therapeutics, Inc. is a United States-based pharmaceutical Company. The Company is developing a proprietary portfolio of patient-targeted, first-in-class monoclonal antibodies designed to treat seriously ill patients with difficult-to-treat diseases. It is engaged in retrometabolic drug design that focuses on the safety of oral therapies for chronic disease. The Companys clinical compounds include naronapride (ATI-7505) for gastrointestinal disorders; budiodarone (ATI-2042, for the treatment of atrial fibrillation; tecarfarin (ATI-5923) for the treatment of anticoagulation; and ATI-9242, for psychiatric disorders.
Employees
56
  1. Stock Market
  2. Stocks
  3. ARYX Stock